Risk factors for mortality in patients with mucormycosis

References

• Roden MM, Zaoutis TE, Buchanan WL, . Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634–653.
   PubMed Web of Science ®Google Scholar
• Singh N, Aguado JM, Bonatti H, . Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis 2009; 200: 1002–1011.
   PubMed Web of Science ®Google Scholar
• Reed C, Bryant R, Ibrahim AS, . Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008; 47: 364–371.
   PubMed Web of Science ®Google Scholar
• Gleissner B, Schilling A, Anagnostopolous I, Siehl I, Thiel E. Improved outcome of zygomycosis in patients with hematological diseases? Leuk Lymphoma 2004; 45: 1351–1360.
   PubMed Web of Science ®Google Scholar
• Shoham S, Magill SS, Merz WG, . Primary treatment of zygomycosis with liposomal amphotericin B: analysis of 28 cases. Med Mycol 2009; 48: 511–517.
   Web of Science ®Google Scholar
• Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000; 30: 851–856.
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Lionakis MS, Lewis RE, . Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005; 191: 1350–1360.
   PubMed Web of Science ®Google Scholar
• Chamilos G, Lewis RE, Hu J, . Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis. Proc Natl Acad Sci USA 2008; 105: 9367–9372.
   PubMed Web of Science ®Google Scholar
• Skiada A, Pagano L, Groll A, . Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect 2011; 17: 1859–1867.
   PubMed Web of Science ®Google Scholar
• Spellberg B, Ibrahim AS, Chin-Hong PV, . The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded placebo controlled trial. J Antimicrob Chemother 2011; 67: 715–722.
   PubMed Web of Science ®Google Scholar
• Ibrahim AS, Gebermariam T, Fu Y, . The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 2007; 117: 2649–2657.
   PubMed Web of Science ®Google Scholar
• Ibrahim AS, Gebremariam T, Lin L, . The high affinity iron permease is a key virulence factor required for Rhizopus oryzae pathogenesis. Mol Microbiol 2010; 77: 587–604.
   Google Scholar
• Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005; 18: 556–569.
   PubMed Web of Science ®Google Scholar
• Ascioglu S, Rex JH, de Pauw B, . Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7–14.
   PubMed Web of Science ®Google Scholar
• Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J Jr, Ibrahim AS. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis 2009; 48: 1743–1751.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Goodman JL, Pappas P, . Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001; 45: 3487–3496.
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Lewis RE. How I treat mucormycosis. Blood 2011; 118: 1216–1224.
   PubMed Web of Science ®Google Scholar
• Reed C, Ibrahim A, Edwards JE Jr, Walot I, Spellberg B. Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother 2006; 50: 3968–3869.
   PubMed Web of Science ®Google Scholar
• Spellberg B, Andes D, Perez M, . Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. Antimicrob Agents Chemother 2009; 53: 3122–3125.
   PubMed Web of Science ®Google Scholar